← Leaderboards
David Porter
University Of Pennsylvania
$3,923,854
Attributed
$5,032,387
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $511.4K · FY2006–21$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$5,032,387 · 3
By mechanism
R01$2,217,067 · 1
P01$2,037,340 · 1
K24$777,980 · 1
Top collaborators
- Carl H. June5 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Marco Ruella$5,145,541
- Carl H. June$35,377,952
- Meenhard Herlyn$50,214,821
- Stephan A Grupp$7,570,044
- Saar Gill$5,197,347
Others in their field
Top investigators on “Allogenic”
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Mary M Horowitz · Medical College Of Wisconsin$47,632,939
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$40,815,122
- Marcel R M Van Den Brink · Sloan-Kettering Institute For Cancer Res$39,678,762
- Bruce R. Blazar · University Of Minnesota$37,193,531
- Megan Sykes · Columbia University Health Sciences$33,587,479
Research focus
AllogenicInfusion ProceduresMalignant NeoplasmsClinical TrialsDesignIn VivoNeoplastic CellNovel StrategiesCellsCell CountLaboratoriesAutologousInnovationCollaborationsCd19 GeneLeadBaseHigh RiskMedicalImmunotherapyB-LymphocytesB Lymphoid MalignancyClinical DataPre-Clinical
Grant awards (16)
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$415,924
P01 · FY2021 · CA · contact PI
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$340,461
P01 · FY2020 · CA · contact PI
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$427,021
P01 · FY2019 · CA · contact PI
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$15,408
P01 · FY2019 · CA · contact PI
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$402,534
P01 · FY2018 · CA · contact PI
Project 1: Overcoming resistance of B cell leukemia to CD19 CAR T Cells.$435,992
P01 · FY2017 · CA · contact PI
CD19 Directed CAR Therapy$237,659
R01 · FY2016 · CA
CD19 Directed CAR Therapy$504,482
R01 · FY2015 · CA
CD19 Directed CAR Therapy$489,347
R01 · FY2014 · CA
CD19 Directed CAR Therapy$474,213
R01 · FY2013 · CA
CD19 Directed CAR Therapy$511,366
R01 · FY2012 · CA
Mid-career investigator award in allogeneic adoptive immunotherapy$155,597
K24 · FY2010 · CA · contact PI
Mid-career investigator award in allogeneic adoptive immunotherapy$155,597
K24 · FY2009 · CA · contact PI
Mid-career investigator award in allogeneic adoptive immunotherapy$155,597
K24 · FY2008 · CA · contact PI
Mid-career investigator award in allogeneic adoptive immunotherapy$155,597
K24 · FY2007 · CA · contact PI
Mid-career investigator award in allogeneic adoptive immunotherapy$155,592
K24 · FY2006 · CA · contact PI